CJC-1295 + Ipamorelin — The Reference Stack

Background

This combination pairs CJC-1295 No DAC (a GHRH analogue) with Ipamorelin (a selective ghrelin receptor agonist). It is the standard reference combination cited in GH-secretagogue research because the two compounds act on different pituitary receptors with complementary mechanisms.

Mechanism

GHRH analogues amplify pituitary somatotroph readiness to release GH; ghrelin receptor agonists trigger the release. Combined administration produces a greater GH pulse than either compound alone — a well-documented pharmacological synergy.

What is proven

Synergy between GHRH and GHRP class compounds at the pituitary is established in human pharmacology studies. Combined GH pulse amplitude exceeds additive expectation. IGF-1 elevation is dose-dependent.

What is NOT proven

No completed Phase 3 outcome trials of this specific combination. Long-term human safety, body-composition and healthspan endpoints rest on pharmacology, not on registrational data.

Open research questions

Whether amplified pulsatile GH release confers durable body-composition or recovery benefits beyond what selective single-receptor agonism delivers; long-term IGF-1 elevation surveillance.

Regulatory status

Not approved by any major regulator.

All Proteus® compounds are sold strictly for in-vitro research. Nothing on this page is medical advice, a treatment claim, or a recommendation for human use. Where compounds are licensed medicines in any jurisdiction, that approval applies to the licensed product supplied through a regulated pharmacy — not to research-grade material.